Barclays PLC 4 D Molecular Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 114,848 shares of FDMT stock, worth $894,665. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114,848

Previous 114,848 -0.0%

Holding current value

$894,665

Previous $1.24 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$10.81 - $27.22 $726,453 - $1.83 Million	67,202 Added 141.04%	114,848 $1.24 Million
Q2 2024 Aug 14, 2024	SELL	$20.93 - $30.01 $3,620 - $5,191	-173 Reduced 0.36%	47,646 $1 Million
Q1 2024 May 15, 2024	SELL	$17.03 - $35.87 $1.04 Million - $2.18 Million	-60,890 Reduced 56.01%	47,819 $1.52 Million
Q4 2023 Feb 15, 2024	BUY	$9.76 - $21.25 $339,394 - $738,947	34,774 Added 47.03%	108,709 $2.2 Million
Q3 2023 Nov 07, 2023	SELL	$12.64 - $19.76 $866,206 - $1.35 Million	-68,529 Reduced 48.1%	73,935 $941,000
Q2 2023 Aug 03, 2023	BUY	$15.16 - $23.26 $1.29 Million - $1.98 Million	85,235 Added 148.94%	142,464 $2.57 Million
Q1 2023 May 04, 2023	BUY	$15.45 - $23.19 $348,490 - $523,073	22,556 Added 65.05%	57,229 $984,000
Q4 2022 Feb 13, 2023	BUY	$6.85 - $25.46 $159,584 - $593,141	23,297 Added 204.79%	34,673 $770,000
Q3 2022 Nov 03, 2022	BUY	$6.96 - $11.48 $12,249 - $20,204	1,760 Added 18.3%	11,376 $91,000
Q2 2022 Aug 12, 2022	SELL	$5.68 - $15.99 $13,291 - $37,416	-2,340 Reduced 19.57%	9,616 $68,000
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $157,340 - $270,683	11,956 New	11,956 $181,000

Others Institutions Holding FDMT

# of Institutions

144

Shares Held

57.7M

Call Options Held

137K

Put Options Held

111K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $252M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account